Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
A new study published in The Lancet finds Keytruda, the PD-1 antibody pembrolizumab, may offer a better safety profile but does not improve outcomes compared with paclitaxel.
Read Source
